Last Updated : July 13, 2023
Details
FilesGeneric Name:
caplacizumab
Project Status:
Complete
Therapeutic Area:
Acquired thrombotic thrombocytopenic purpura (aTTP)
Manufacturer:
sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cablivi
Project Line:
Reimbursement Review
Project Number:
SR0736-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Submission Type:
Resubmission
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Recommendation Type:
Do not reimburse
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | May 09, 2022 |
|---|---|
| Call for patient/clinician input closed | July 04, 2022 |
| Clarification: - Patient input submission received from Answering T.T.P. (Thrombotic Thrombocytopenic Purpura) Foundation | |
| Submission received | June 07, 2022 |
| Submission accepted | June 21, 2022 |
| Review initiated | June 22, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | September 07, 2022 |
| Deadline for sponsors comments | September 16, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | October 14, 2022 |
| Expert committee meeting (initial) | October 26, 2022 |
| Draft recommendation issued to sponsor | November 07, 2022 |
| Draft recommendation posted for stakeholder feedback | November 17, 2022 |
| End of feedback period | December 01, 2022 |
| Clarification: - Reconsideration: major revisions requested by sponsor | |
| Expert committee meeting | March 22, 2023 |
| Final recommendation issued to sponsor and drug plans | April 05, 2023 |
| Final recommendation posted | April 24, 2023 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | April 20, 2023 |
| CADTH review report(s) posted | July 13, 2023 |
Files
Last Updated : July 13, 2023